CA-KRAKEN
11.2.2021 15:32:09 CET | Business Wire | Press release
Kraken Digital Asset Exchange, one of the world’s largest cryptocurrency exchanges, today announced its backing of the newly launched Kraken Ventures, an independent investment fund targeting early stage companies and protocols across the crypto and fintech ecosystem. The fund will invest in the technologies powering the next wave of crypto and fintech innovation and provide entrepreneurs with the financial resources and industry expertise needed to build and scale their business.
Kraken Ventures will focus on areas including fintech, crypto companies & protocols, decentralized finance (DeFi) as well as enabling technologies such as AI, Machine and Deep Learning, Reg Tech, and cybersecurity. Kraken Ventures offers the best of both worlds in being a completely autonomous fund that’s backed by the resources and expertise of Kraken.
Led by a team with extensive experience in the crypto and financial services industry and leveraging its strategic partnership with Kraken, portfolio companies get access to the ideal environment for their teams to collaborate across the Kraken and broader fintech ecosystem. The fintech and crypto ecosystems will continue to be drawn closer together and Kraken Ventures will be investing at the intersection of these two dynamic industries.
Jesse Powell, co-founder and CEO of Kraken said: “As we enter the crypto industry’s next growth phase, Kraken Ventures will support entrepreneurs in making the financial system more open, inclusive, and transparent. With a strong team in place, Kraken Ventures offers the right combination of resources to bring the best ideas to their full potential. We’ve arrived at the point where crypto is starting to show its true potential, transforming the financial services industry and creating truly global, digital economies.”
Kraken Ventures will be led by Brandon Gath, who has 20 years of experience in the financial services and crypto industries. He most recently served as the Head of Corporate Development at Kraken and prior to joining Kraken helped lead CME Ventures, where he was an early investor in numerous unicorn startups across fintech, AI, Deep Learning, Quantum Computing and Crypto. He led early investments in Orbital Insight, Crosslend, Digital Currency Group, Nervana Systems, Crypto Facilities, Privitar, and Fortscale. Brandon has a wealth of professional experience ranging across venture capital, M&A, investing banking, and consulting. He holds an MBA from the University of Chicago in Entrepreneurial Finance.
Brandon Gath, General Partner of Kraken Ventures said: “Fintech and specifically crypto technology provides the opportunity to drastically change how businesses and consumers exchange and store value, invest, lend, borrow, and conduct global commerce. We take a long-term view on investing to add value from inception through each growth phase of our portfolio companies’ evolution. We will take a hands-on approach with our portfolio companies to provide guidance, new commercial opportunities and additional capital support. The possibility to leverage Kraken’s experience building a truly global, scalable platform enables us to support our portfolio companies from inception to market leadership. We’ve already identified some of the best opportunities out there and expect to announce our first investments in the near future.”
Brandon will be joined by Kirill Gourov and Akshi Federici . Kirill currently supports strategic investment for Kraken and previously managed blockchain investments for a New York-based multifamily office. Prior to this, he led blockchain strategy efforts at Expand Research, a subsidiary of The Boston Consulting Group. He has been actively involved in the Bitcoin community since early 2013 and has over 7 years of experience in the blockchain industry including investment, strategy development for both public and private chain applications, and business development for blockchain projects. Akshi Federici is a seasoned strategic operator with over 15 years of experience in the financial services and cryptocurrencies industries with The Boston Consulting Group, BlackRock, Conde Nast, ConsenSys, and Kraken.
For more information, please visit www.krakenventures.com
About Kraken
Based in San Francisco, Kraken is the world’s largest global digital asset exchange based on euro volume and liquidity. Kraken’s clients trade more than 50 digital assets and 7 different fiat currencies, including EUR, USD, CAD, GBP, JPY, CHF and AUD. Kraken was founded in 2011 and is the first digital asset exchange to have its market data displayed on the Bloomberg Terminal and one of the first to offer spot trading with margin, regulated derivatives and index services. Kraken is trusted by more than 5 million traders, institutions and authorities around the world.
Kraken is backed by investors including Hummingbird Ventures, Blockchain Capital and Digital Currency Group, among others. For more information about Kraken, please visit www.kraken.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005504/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom